ROSSARI

Rossari Biotech Share Price

 

 

Invest in Rossari Biotech with 3.49X leverage

Invest with MTF

Performance

  • Low
  • ₹576
  • High
  • ₹594
  • 52 Week Low
  • ₹566
  • 52 Week High
  • ₹885
  • Open Price₹582
  • Previous Close₹582
  • Volume32,390

Investment Returns

  • Over 1 Month -7.74%
  • Over 3 Month -6.21%
  • Over 6 Month -15.63%
  • Over 1 Year -29.52%

Smart Investing Starts Here Start SIP with Rossari Biotech for Steady Growth!

Invest Now

Rossari Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.5
  • PEG Ratio
  • -15.2
  • Market Cap Cr
  • 3,207
  • P/B Ratio
  • Average True Range
  • 15.87
  • EPS
  • 24.67
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -11.13
  • RSI
  • 27.41
  • MFI
  • 36.95

Rossari Biotech Financials

Rossari Biotech Technicals

EMA & SMA

Current Price
₹579.05
-2.65 (-0.46%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹605.65
  • 50 Day
  • ₹623.25
  • 100 Day
  • ₹639.55
  • 200 Day
  • ₹666.40

Resistance and Support

582.83 Pivot Speed
  • R3 608.32
  • R2 601.08
  • R1 590.07
  • S1 571.82
  • S2 564.58
  • S3 553.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Rossari Biotech is a leading specialty chemicals manufacturer in India, offering solutions across home and personal care, performance chemicals, and textile specialty chemicals. With three manufacturing plants, it serves clients in over 25 countries with sustainable chemical solutions.

Rossari Biotech has an operating revenue of Rs. 2,222.12 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 9% is okay, ROE of 11% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 88 indicates it belongs to a poor industry group of Diversified Operations and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Rossari Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-10-15 Quarterly Results
2025-07-19 Quarterly Results
2025-04-25 Audited Results & Final Dividend
2025-01-21 Quarterly Results
2024-10-19 Quarterly Results
Date Purpose Remarks
2025-06-20 FINAL Rs.0.50 per share(25%)Final Dividend
View Rossari Biotech Dividend History Arrow

Rossari Biotech F&O

Rossari Biotech Shareholding Pattern

68.17%
13.27%
4.36%
2.7%
0%
9.47%
2.03%

About Rossari Biotech

  • NSE Symbol
  • ROSSARI
  • BSE Symbol
  • 543213
  • Managing Director
  • Mr. Sunil Chari
  • ISIN
  • INE02A801020

Similar Stocks to Rossari Biotech

Rossari Biotech FAQs

Rossari Biotech share price is ₹579 As on 10 December, 2025 | 23:07

The Market Cap of Rossari Biotech is ₹3206.9 Cr As on 10 December, 2025 | 23:07

The P/E ratio of Rossari Biotech is 23.5 As on 10 December, 2025 | 23:07

The PB ratio of Rossari Biotech is 2.7 As on 10 December, 2025 | 23:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23